Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ZVSA | US
-0.03
-11.50%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.23
0.26
0.26
0.23
ZyVersa Therapeutics Inc. a clinical stage biopharmaceutical company develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200 a cholesterol efflux mediator which is in Phase 2a clinical trial to the treatment of multiple renal indications such as focal segmental glomerulosclerosis alport syndrome and diabetic nephropathy; and IC 100 a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics Inc. is headquartered in Weston Florida.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
94.4%1 month
142.2%3 months
176.6%6 months
145.6%0.00
-
0.29
-
-
-2.21
-
-
-10.25M
247.17K
247.17K
-
-
-
-
-152.23
0.32
2.22
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.05
Range1M
0.12
Range3M
0.17
Rel. volume
1.21
Price X volume
10.45K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.0005 | 259.17K | -50.00% | n/a | 20.48% |
| Windtree Therapeutics Inc | WINT | Biotechnology | 0.01 | 36.80K | -25.93% | n/a | 36.99% |
| Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0.0001 | 12.68K | n/a | 113.12% | |
| Syros Pharmaceuticals Inc | SYRS | Biotechnology | 0.0002 | 5.36K | 0.00% | n/a | -954.99% |
| EFTR | EFTR | Biotechnology | 0.0002 | 940.83 | n/a | 2315.36% | |
| XOMAP | XOMAP | Biotechnology | 25.885 | 0 | 0.45% | 26.27 | 121.93% |
| XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.3 | 0 | -0.49% | 25.57 | 121.93% |
| SABSW | SABSW | Biotechnology | 0.0318 | 0 | 0.17 | 11.58% | |
| Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 1.83 | 0 | 1.67% | n/a | 5.40% |
| REVBW | REVBW | Biotechnology | 0.0091 | 0 | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.21 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | 0.00 | 41.03 | Cheaper |
| Price to Book | 0.29 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 176.56 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 247.17K | 3.66B | Emerging |